Login to Your Account

Mylan, Biocon get CRL for Neulasta biosimilar

By Jennifer Boggs
Managing Editor

Tuesday, October 10, 2017

Biocon Ltd. said Tuesday the FDA issued a complete response letter for partner Mylan NV's BLA for MYL-1401H, a proposed biosimilar of Amgen Inc.'s Neulasta, the latest biosimilar version of the long-acting G-CSF drug to hit a regulatory snag.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription